Summary of Interim Report
First quarter of 2024
The group in total
- Net sales 0.0 MSEK (0.0 MSEK)
- Other income 0.0 MSEK (0.3 MSEK)
- R&D expenses for the quarter amounted to 0.5 MSEK (7.0 MSEK)
- Profit after tax amounted to -12.4 MSEK (-5.4 MSEK)
- Earnings per share for the quarter amounted to -0.11 SEK (-0.10 SEK)
- Cash flow from operating activities amounted to -2.0 MSEK (-2.2 MSEK)
- Liquid assets on the balance sheet date amounted to 0.5 MSEK (8.9 MSEK)
- Equity as of June 30 amounted to 20.8 MSEK (60.6 MSEK)
The period January-June 2024
The group in total
- Net sales 0.0 MSEK (6.5 MSEK)
- Other income 0.0 MSEK (0.3 MSEK)
- R&D expenses for the quarter amounted to 1.5 MSEK (15.6 MSEK)
- Profit after tax amounted to -24.3 MSEK (-15.5 MSEK)
- Earnings per share for the period amounted to -0.22 SEK (-0.16 SEK)
- Cash flow from operating activities amounted to -9.8 MSEK (-11.3 MSEK)
This interim report has been prepared for the group in accordan ce with IAS 34 Interim Reporting and the Annual Accounts Act (ÅRL) as well as IFRS, as adopted by the EU. For the parent company, the Annual Accounts Act (ÅRL) and the Council for Financial Reporting Recommendation RFR 2 Accounting for legal entities have been applied.
For more information, visit the Klaria Pharma Holding website klaria.com or contact:
investor.relations@klaria.com
This is Klaria Pharma Holding AB
Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.
